| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/314711 |
| P698 | PubMed publication ID | 10191234 |
| P2093 | author name string | Crawford JM | |
| Montefiori DC | |||
| Buchbinder SP | |||
| Scheer S | |||
| Bradney AP | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 4 | |
| P304 | page(s) | 1264-1267 | |
| P577 | publication date | 1999-05-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors | |
| P478 | volume | 179 |
| Q45723228 | A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1. |
| Q33522232 | A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein |
| Q36229149 | A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells |
| Q39193318 | Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. |
| Q39305772 | Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization |
| Q35956940 | Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity |
| Q37773298 | Carbohydrate targets in HIV vaccine research: lessons from failures. |
| Q33825229 | Characterization of primary isolate-like variants of simian-human immunodeficiency virus |
| Q35857480 | Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections |
| Q43215260 | Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers |
| Q33392723 | Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression |
| Q45406304 | Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. |
| Q34648079 | Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1 |
| Q24815687 | Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant |
| Q39324895 | Genetic variability of the V1 and V2 env domains of SIVcpz-ant and neutralization pattern of plasma viruses in a chimpanzee infected naturally |
| Q30701127 | Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12 |
| Q34292622 | Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients |
| Q36376194 | Impairment of CD4(+) T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants |
| Q34464860 | Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. |
| Q33810203 | Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees |
| Q33410826 | International network for comparison of HIV neutralization assays: the NeutNet report |
| Q41827503 | Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. |
| Q33504604 | Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection |
| Q28477253 | Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies |
| Q34647680 | Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy |
| Q34419527 | Neutralizing antiviral antibody responses |
| Q34619876 | Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. |
| Q35022653 | Public versus personal serotypes of a viral quasispecies. |
| Q33640144 | R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models |
| Q29618603 | Rapid evolution of the neutralizing antibody response to HIV type 1 infection |
| Q34332009 | Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa |
| Q39605628 | Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course |
| Q24564623 | Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection |
| Q34092644 | Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution |
| Q34415389 | Specificity of the autologous neutralizing antibody response |
| Q36856960 | Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors |
| Q34312037 | Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus |
| Q33504607 | The cat and mouse of HIV-1 antibody escape |
| Q34284913 | Using HIV-1 sequence variability to explore virus biology |
| Q35080884 | Viral persistence in vivo through selection of neutralizing antibody-escape variants. |
| Q35948073 | Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions. |
| Q45722197 | Virion-bound ICAM-1 and activated LFA-1: a combination of factors conferring resistance to neutralization by sera from human immunodeficiency virus type 1-infected individuals independently of the disease status and phase |
| Q35192660 | epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals |
Search more.